logo
  Join        Login             Stock Quote

Cubist (CBST): Entereg Phase 4 Study In Patients Undergoing Radical Cystectomy Met Primary Endpoints

 April 17, 2012 08:09 PM
 


Cubist Pharmaceuticals Inc. (NASDAQ:CBST) said a Phase 4 study of Entereg (alvimopan) in patients undergoing radical cystectomy met its primary endpoint of time to achieve recovery of both upper and lower gastrointestinal (GI) function.

In this study, the adverse event profile was comparable between Entereg and placebo. This study was a post-approval commitment with the U.S. Food and Drug Administration (FDA). The company expects to submit a supplemental New Drug Application by the end of 2012.

All secondary endpoints, including length of hospital stay, also achieved statistical significance. Delayed recovery of GI function is one of the most common complications prolonging hospital stay in patients undergoing radical cystectomy.

[Related -Cubist Pharmaceuticals Inc. (CBST): All-Time Highs On The Horizon?]

The accelerated recovery of GI function and associated reduction in length of stay suggests that Entereg has the potential to improve surgical outcomes for patients undergoing radical cystectomy.

The Phase 4 investigation was a randomized, double-blind, placebo-controlled study of Entereg 12 mg or placebo administered by mouth once preoperatively and twice daily (BID) postoperatively for a maximum of 15 hospital doses in 280 patients undergoing radical cystectomy. Assessments for efficacy were performed over a 10-day observation period and safety evaluated through 30 days after the last dose of study drug.

The most frequently reported treatment-emergent adverse events in the trial were hypokalemia, anemia and postoperative ileus. The rate of postoperative ileus was higher in the placebo-treated group compared to the Entereg-treated group.

[Related -Stock Upgrades And Downgrades: CBST, CCL, CMA, COH, OIS, SF, VFC, WCG]

The incidence of all other treatment-emergent adverse events, including hypokalemia and anemia, was comparable between the two groups. The majority of treatment-emergent adverse events were mild or moderate in severity.

The incidence of severe treatment-emergent adverse events was comparable between the two treatment groups. In this study, cardiovascular adverse events were adjudicated by an external independent clinical committee. The incidence of cardiovascular events was 15% for placebo-treated patients and 8.4% for Entereg-treated patients, which was not statistically different.

Radical cystectomy is a major abdominopelvic surgical procedure performed on patients with urinary bladder cancer. Delayed recovery of GI function is one of the most common complications associated with radical cystectomy.

This procedure generally involves removal of the urinary bladder and associated organs within the pelvis as necessary. The primary goal of radical cystectomy is to resect local and locally metastatic disease with functional urinary tract reconstruction.

CBST closed Tuesday's regular trading up 0.80% at $40.22. The stock has been trading between $28.82 and $44.95 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.